Zacks Research Has Bearish Estimate for Neogen Q3 Earnings

Neogen Co. (NASDAQ:NEOG - Free Report) - Equities research analysts at Zacks Research decreased their Q3 2025 EPS estimates for Neogen in a research note issued on Wednesday, February 12th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.11 per share for the quarter, down from their previous forecast of $0.12. The consensus estimate for Neogen's current full-year earnings is $0.38 per share.

Several other research firms also recently weighed in on NEOG. Guggenheim assumed coverage on Neogen in a research note on Thursday, December 19th. They issued a "buy" rating and a $15.00 price target for the company. Piper Sandler restated a "neutral" rating and set a $13.00 target price (down previously from $16.50) on shares of Neogen in a research report on Tuesday, January 21st.

Neogen Price Performance

Shares of NASDAQ NEOG traded down $0.10 during mid-day trading on Monday, reaching $10.29. The company's stock had a trading volume of 2,620,624 shares, compared to its average volume of 2,762,273. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.77 and a quick ratio of 2.46. Neogen has a 52 week low of $9.70 and a 52 week high of $18.58. The stock has a fifty day moving average of $11.61 and a two-hundred day moving average of $14.05. The firm has a market capitalization of $2.23 billion, a PE ratio of -4.70 and a beta of 1.23.

Neogen (NASDAQ:NEOG - Get Free Report) last released its earnings results on Friday, January 10th. The company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of ($0.01) by $0.12. Neogen had a negative net margin of 52.12% and a positive return on equity of 2.89%. The company had revenue of $231.30 million for the quarter, compared to analysts' expectations of $227.16 million. During the same quarter in the previous year, the company earned $0.11 EPS. Neogen's revenue for the quarter was up .7% on a year-over-year basis.

Institutional Investors Weigh In On Neogen

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in shares of Neogen by 9.8% in the 4th quarter. Vanguard Group Inc. now owns 21,637,251 shares of the company's stock worth $262,676,000 after purchasing an additional 1,928,491 shares during the period. Norges Bank purchased a new position in Neogen during the fourth quarter worth $212,171,000. William Blair Investment Management LLC increased its position in Neogen by 8.1% during the fourth quarter. William Blair Investment Management LLC now owns 14,346,759 shares of the company's stock valued at $174,170,000 after acquiring an additional 1,074,825 shares during the last quarter. Conestoga Capital Advisors LLC increased its position in Neogen by 24.5% during the third quarter. Conestoga Capital Advisors LLC now owns 8,706,224 shares of the company's stock valued at $146,352,000 after acquiring an additional 1,711,238 shares during the last quarter. Finally, Bamco Inc. NY raised its stake in shares of Neogen by 16.2% in the fourth quarter. Bamco Inc. NY now owns 8,485,308 shares of the company's stock valued at $103,012,000 after acquiring an additional 1,182,193 shares during the period. 96.73% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Neogen news, CEO John Edward Adent bought 23,035 shares of Neogen stock in a transaction dated Thursday, January 16th. The shares were purchased at an average cost of $11.03 per share, for a total transaction of $254,076.05. Following the acquisition, the chief executive officer now directly owns 269,164 shares in the company, valued at approximately $2,968,878.92. This represents a 9.36 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CFO David H. Naemura bought 14,800 shares of the firm's stock in a transaction dated Thursday, January 16th. The shares were acquired at an average price of $11.11 per share, for a total transaction of $164,428.00. Following the completion of the transaction, the chief financial officer now directly owns 61,434 shares in the company, valued at approximately $682,531.74. This represents a 31.74 % increase in their position. The disclosure for this purchase can be found here. 1.13% of the stock is owned by company insiders.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.